Core Viewpoint - The arbitration case regarding the exclusive agency rights for AestheFill products has seen new developments, with REGEN Biotech, Inc. receiving a decision from the Shenzhen International Arbitration Court that revokes previous temporary measures against them, although the case is still under review [2][8]. Group 1: Arbitration Developments - On January 30, 2026, REGEN received a decision from the Shenzhen International Arbitration Court that revoked the temporary measures imposed on September 10, 2025, which restricted REGEN from selling AestheFill products in China and recognized DaTou Company as the exclusive distributor [2][8]. - The temporary measures had been in place since a request from DaTou Company, which claimed exclusive rights to AestheFill products in China [7][8]. - The arbitration case is ongoing, and the recent decision does not represent a final ruling on the matter [8]. Group 2: Company Actions and Responses - DaTou Company was granted exclusive distribution rights for AestheFill products in mainland China through an agreement signed in August 2022 [3]. - In July 2025, REGEN sent a termination notice to DaTou, claiming violations of the agreement and citing reputational damage due to actions by DaTou's parent company, Jiangsu Wuzhong [4][5]. - Jiangsu Wuzhong has publicly defended DaTou's rights, asserting that the exclusive agency agreement remains valid until August 28, 2032 [4]. Group 3: Financial Performance - Jiangsu Wuzhong's stock was delisted on December 31, 2025, due to significant financial irregularities, including inflated revenues and undisclosed related-party transactions [9]. - AestheFill sales accounted for 20.42% of Jiangsu Wuzhong's revenue in 2024, with a significant contribution to its gross profit [10]. - For the first three quarters of 2025, Jiangsu Wuzhong reported a 38.85% decline in revenue, leading to a net loss [10]. Group 4: Market Context - Aimeike, the parent company of REGEN, has experienced declining revenue and net profit, with a 21.49% drop in revenue for the first three quarters of 2025 [11]. - The overall medical aesthetics market in China is facing slower growth, attributed to increased competition and a challenging macroeconomic environment [11].

Core Viewpoint - The dispute between Aimeike and Jiangsu Wuzhong regarding the exclusive agency rights for AestheFill has escalated, with Aimeike asserting legal grounds for terminating the agreement due to alleged violations by Jiangsu Wuzhong and its affiliates [1][3][4]. Group 1: Company Actions and Responses - Aimeike claims that Jiangsu Wuzhong's subsidiary, Datou Medical, has transferred its exclusive distribution rights to its controlling shareholder, Wu Zhongmei, which violates the exclusive distribution agreement [1][3]. - Aimeike emphasizes that the termination of the agreement with Datou Medical is legally justified and will rely on judicial rulings for any disputes [1]. - Aimeike refutes allegations of supply delays, stating that the last shipment to Datou Medical occurred in mid-July and that supply to the Chinese market has slightly increased compared to the same period last year [1][2]. Group 2: Jiangsu Wuzhong's Position - Jiangsu Wuzhong disputes Aimeike's claims, asserting that Datou Medical has not transferred agency rights and that the exclusive agency agreement does not allow for termination based on administrative penalties against related parties [4]. - Jiangsu Wuzhong accuses Aimeike of intentionally delaying shipments to Datou Medical, which has led to product shortages and harmed consumer rights [4]. - Jiangsu Wuzhong's official statement claims that Aimeike is abusing its market position to disrupt the supply chain, which contradicts the spirit of the contract [4]. Group 3: Market Reactions - Following the announcement of the dispute, Jiangsu Wuzhong's stock price fell to 1.62 yuan per share, a decline of 4.71%, with a market capitalization of 1.154 billion yuan [6]. - In contrast, Aimeike's stock rose to 186.83 yuan per share, an increase of 0.99%, with a market capitalization of 56.533 billion yuan [6].

Core Viewpoint - The termination of the exclusive distribution agreement between Regen and Datou Medical is expected to significantly impact the sales and profits of *ST Suwu's medical aesthetics segment, as it will lose the exclusive rights to sell the AestheFill product in mainland China [1][4]. Group 1: Company Actions - On July 18, 2025, Regen sent a termination letter to Datou Medical, revoking its status as the exclusive distributor for the AestheFill product in mainland China [1][3]. - Following the termination, Datou Medical is prohibited from conducting any business activities as the exclusive distributor and will not be able to place any further orders with Regen [3][4]. - *ST Suwu has initiated a response plan upon receiving the termination letter and is prepared to take legal action if necessary to protect its rights [5]. Group 2: Financial Impact - In 2024, AestheFill generated sales revenue of 326 million yuan, accounting for 20.42% of *ST Suwu's total revenue, with a gross profit of 269 million yuan, representing 34.80% of the company's gross profit [4]. - In the first quarter of 2025, AestheFill sales revenue reached 113 million yuan, making up 35.55% of the company's revenue, with a gross profit of approximately 92.44 million yuan, which is 45.77% of the total gross profit [4]. - The loss of exclusive distribution rights is expected to lead to a significant decline in revenue and profit for the medical aesthetics segment in the second half of 2025 [4]. Group 3: Background Information - The exclusive distribution agreement was originally signed between REGEN and Datou Medical, with the latter acquiring exclusive rights to AestheFill in mainland China in August 2022 [2]. - The agreement was violated by Datou Medical, which allegedly transferred the exclusive distribution business to its controlling shareholder, Jiangsu Wuzhong Meisheng Biotechnology Co., Ltd., leading to the termination [3].

Core Viewpoint - The company *ST Suwu (600200.SH)* faces potential loss of exclusive distribution rights for AestheFill products in mainland China due to a termination notice from Regen Biotech, which could significantly impact its revenue and profit from the medical aesthetics segment [1][2][3] Group 1: Agreement and Sales Performance - DaTou Medical obtained exclusive distribution rights for AestheFill products in mainland China through an agreement effective until August 28, 2032 [1] - In 2024, AestheFill sales revenue reached 326.41 million yuan, accounting for 20.42% of the company's total revenue, with a gross profit of 268.84 million yuan, representing 34.80% of total gross profit [3] - In Q1 2025, AestheFill sales revenue was 112.77 million yuan, making up 35.55% of the company's total revenue, with a gross profit of 92.44 million yuan, which is 45.77% of total gross profit [3] Group 2: Termination Notice and Company Response - Regen issued a termination notice citing violations of the agreement by DaTou Medical, including the alleged transfer of exclusive distribution rights to its controlling shareholder [2] - The termination would revoke DaTou Medical's status as the exclusive distributor for AestheFill products, halting any business activities under this capacity [2] - The company has initiated a response plan and is in communication with Regen, considering legal action to protect its rights, asserting that it has not transferred the exclusive rights [3]